Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Annals of Hematology

• Publication date

  2008-05-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00277-008-0501-0PMID 18463870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen

  2009cited by this paper
• The emerging role of novel therapies for the treatment of relapsed myeloma.

  2007cited by this paper
• MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma.

  2007cited by this paper
• Multiple myeloma. Clinical practice guidelines in oncology.

  2007cited by this paper
• Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis

  2007cited by this paper
• Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

  2007cited by this paper
• Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.

  2007cited by this paper
• Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.

  2007cited by this paper
• New drugs for myeloma.

  2007cited by this paper
• Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

  2007cited by this paper
• Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma

  2006cited by this paper
• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

  2006cited by this paper
• Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

  2006cited by this paper
• Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

  2006influential reference
• Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  2005influential reference
• Millennium Pharmaceuticals, Inc.

  2004cited by this paper
• Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.

  2004cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• Common Terminology Criteria for Adverse Events v3.0 (CTCAE)

  2003cited by this paper
• Review of 1027 patients with newly diagnosed multiple myeloma.

  2003cited by this paper
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003influential reference
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper

• Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

  2020cites this paper
• Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects

  2017cites this paper
• Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study

  2017cites this paper
• Delayed Onset Tumor Lysis Syndrome after Initial Pomalidomide Treatment in a Patient with Refractory Multiple Myeloma

  2016cites this paper
• A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

  2016influential citation
• Molecular basis of resistance to proteasome inhibitors in hematological malignancies.

  2015cites this paper
• Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma

  2014cites this paper
• Primary hepatocellular carcinoma (“hepatoid” carcinoma) of the pancreas: a case report and review of the literature

  2013cites this paper
• Spontaneous tumor lysis syndrome in breast cancer: a case report and discussion

  2013cites this paper
• Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma

  2013cites this paper
• Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma

  2013cites this paper
• Severe hyperphosphatemia in a patient with chronic kidney disease and multiple myeloma–to strengthen the case toward renal replacement therapy?

  2013cites this paper
• CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.

  2012cites this paper
• Durable remission with salvage second autotransplants in patients with multiple myeloma

  2012cites this paper
• Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma

  2012cites this paper
• A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma

  2012cites this paper
• A review of tumour lysis syndrome with targeted therapies and the role of rasburicase

  2011cites this paper
• Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

  2011cites this paper
• Therapy of relapsed and refractory multiple myeloma.

  2011cites this paper
• Bortezomib in relapsed and relapsed/ refractory multiple myeloma

  2011cites this paper
• Terapia nawrotowego i opornego szpiczaka plazmocytowego Therapy of relapsed and refractory plasma cell myeloma

  2011cites this paper
• Management of hyperuricemia in adults with or at risk of tumor lysis syndrome

  2011cites this paper
• Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.

  2010cites this paper
• Advances in treatment for relapses and refractory multiple myeloma

  2010cites this paper
• The proteasome inhibitor CEP‐18770 enhances the anti‐myeloma activity of bortezomib and melphalan

  2010cites this paper
• Proteasome inhibition and its therapeutic potential in multiple myeloma

  2010cites this paper
• "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

  2010cites this paper
• Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

  2010cites this paper
• Treatment of relapsed/refractory multiple myeloma.

  2009cites this paper
• Current World Literature

  2009cites this paper
• Novel Agents for Relapsed and/or Refractory Multiple Myeloma

  2009cites this paper
• Proteasome inhibitors in the treatment of multiple myeloma

  2009cites this paper
• Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

  2009cites this paper
• DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

  2009cites this paper
• Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen

  2009cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2008cites this paper
• Bortezomib in the front-line treatment of multiple myeloma

  2008cites this paper
• Bibliography. Current awareness. Pharmacoepidemiology and drug safety.

  2008cites this paper
• Bortezomib, low‐dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

  2007cites this paper